Abstract Patients with sickle cell disease frequently require red blood cell transfusions . However, transfusions can cause delayed hemolytic transfusion reaction (DHTR), a serious and potentially life-threatening complication of alloimmunization that results in hemolysis of transfused as well as patients' own red cells . Although we are beginning to understand some of the pathophysiology and risk factors associated with alloimmunization, optimal management of DHTR in this patient population is still under debate. Here, I will review the clinical features, pathophysiology, laboratory evaluation, current strategies for management and prevention of DHTRs. Given that DHTRs are associated with massive hemolysis, it is reco mmended that all patients with sickle cell disease receiving transfusions are carefully and systematically monitored after each transfusion.
Background
Red blood cell (RBC) transfusion is often used for treatment and management of sickle cell disease (SCD). The purpose of RBC transfusion is to increase oxygen distribution to the tissues and/or to replace the rig id sickleshaped RBCs with healthy deformable RBCs. However, because of the frequency of trans fusions in their life-t ime, patients with SCD beco me exposed to RBCs alloantigens of donor units, making them more likely to produce alloantibodies, which in turn puts them at risk for delayed hemolytic transfusion reactions (DHTRs). In addition, exchange transfusions, which are often used for these patients, may increase the risk o f DHTR. Th is is because there is increased red cell utilizat ion with exchange transfusions, with more exposure to foreign erythrocyte antigens and increased volume of transfused erythrocytes susceptible to hemolysis during DHTR. A llo immun izat ion in SCD has a reported incidence of 20% to 50% [1, 2] . Red cell alloimmunizat ion is frequent because of the antigen disparities between patients of African descent and donors of European ancestry [3, 4, 5] . The DHTR syndrome is a serious and potentially lifethreatening complication of allo immun ization, wh ich has a reported incidence of 4% to 11% [1, 3] . It is characterized by recurrence of d isease complications such as recipient RBCs destruction. In some cases, no detectable antibody is present. DHTR is associated with a significant morb idity or mortality. The pathophysiology of this syndrome remains unclear; especially when there is no detectable antibody. Accelerated apoptosis of donor RBCs has been recently suggested as a potential mechanis m of recipient RBC destruction during DHTR [6, 7, 8] . Signs and symptoms of DHTR are quite similar to those of vaso-occlusive crisis (VOC) in patients with sickle cell disease [9, 10] . Th is makes the diagnosis of DHTR and appropriate therapeutic decisions still a challenging issue to clinicians in charge of patients affected by DHTR.
In this review, we p resent a synthesis of the current understanding of the pathophysiology of allo immun izat ion, as well as the clinical features, diagnosis and management strategies of DHTR in SCD (Tab le 1 and Table 2 ).
Pathophysiology
The pathophysiology of DHTR in SCD patients has not been completely elucidated. Classically, DHTR is ascribed to a reaction between anti-RBC antibodies produced by the recipient and antigens expressed by the donor RBCs [6, 7, 8, 9, 10] . It remains unclear why some patients develop strong alloantibody responses following initial RBC transfusions, while others do not despite mult iple transfusions. However, anti-RBC antibodies are often undetectable in SCD patients with DHTR [1, 4, 7] . The high proportion of DHTR cases without identifiable antibodies suggests that multip le factors are involved in the pathophysiology of this life-threatening comp lication.
1-Differences in erythrocyte antigens between blood donors of European descent and patients of African descent.
It is generally accepted that the high rate of allo immun izat ion in SCD patients is main ly due to the polymorphic differences in immunologic RBC antigens between the predominantly wh ite general blood donors and patients of predominantly African descent [11, 12] . In the countries, where donors and patients are racially more homogeneous, low rates of alloimmunization have been reported [13, 14] . These reports support the idea that racial antigenic differences account for increased allo immun izat ion rates.
Antigenic differences between donors and SCD patients could be represented at three levels of co mplexity:
-First, there is a substantial difference in the prevalence of some co mmon but highly immunogenic RBC antigens between donors and transfusion recipients. The following blood groups: C and E in the Rhesus (RH), K in the Kell (KEL), Fy a in the Duffy (FY), Jk b in the Kidd (JK), and S in the MNS are more frequently encountered in whites than in black African descents.
-Second, other antigens are more immunogenic in blacks: RH32 encoded by the RN haplotype, DAK encoded by DIIIa, DOL, and RN [15, 16] , Js a and Co b antigens [17, 18] .
-Third, alloimmun ization in SCD patients is also possible when the recip ient lacks an antigen that is expressed in almost all donor RBCs. These main concerned blood groups are RH (the absence of Hs, HrB, or RH46), KEL (the absence of Jsb) and of MNS (absence of U) [19] .
Partial antigens are frequently encountered in AfroCarribean patients. These patients ma ke alloantibodies when exposed to the complete antigen through transfusion or pregnancy.
2-The theory of apoptosis According to one hypothesis, stored donor RBCs may experience accelerated eryptosis in the bloodstream of SCD patients, with externalization of the phosphatidylserine (PS) memb rane at the outer surface of the cell [6] . The exposure of PS in RBC has recently been reported to be significantly increased following the incubation of donor RBC with pre -transfusion plasma samples fro m SCD patients who develop DHTR co mpared to other SCD patients who do not develop this complication [8] . Furthermore, the exposure of PS in RBC progressively increased in patients with DHTR, particu larly when donor erythrocytes were completely destroyed. As PS exposure is a signal for apoptosis, this increases the suicidal death of RBC. PS exposure may contribute to the increased hemolysis observed during DHTR. The ro le of PS in RBC adhesion to endothelium may also, at least in part, exp lain the severe pain episodes observed during DHTR. RBCs may be rapid ly destroyed by macrophages, which are probably activated. By performing a hemoglobin electrophoresis, it is easy to show that donor RBCs are often completely destroyed [20] . The reason for this is obvious when new antibodies directed against the transfused units are observed. However, alloantibodies may not be detected at the time of the DHTR, may become detected later, or may never be detected [21] . The worsening anemia probably represents a co mbination of hemolysis of transfused cells, hyperhemolysis related to the immunologic response, and suppression of erythropoesis.
The so-called "bystander hemolysis" may be a major mechanis m in DHTR in SCD. In addition to alloimmune and autoimmune RBC lysis, a third category of immune destruction of blood cells should be recognized [22] . This additional immunologic response occurs when RDC are injured by immunologic reactions in which the RBC act as "innocent bystanders." Bystander hemolysis may be defined as the destruction of antigen-negative RBCs during immune hemolysis of antigen-positive RBCs. King et al. suggested the bystander haemolysis mechanism [23] . One mechanism by wh ich an immune response to an exogenous antigen leads to the destruction of autologous RBC is the temporary development of autoantibodies. This is actually an alloimmune reaction which results in a temporary state of "pseudo"-autoimmun ity. Although originally described as a type of hemo lysis of autologous cells, the concept of bystander immune cytolysis has been extended to include other instances in which immune destruction of cells is caused by antibody that is not developed in response to intrinsic antigens on the cell being lysed. Bystander hemolysis during DHTR may occur following activation of co mplement as a result of the reaction of alloantibodies with transfused RBCs or other antibody reactions with transfused foreign antigens, leading to the attachment o f act ivated comp lement components to autologous RBCs. The delayed form of DHTR represents a typical example of the bystander hemolytic mechanism [24] . The suppression of erythropoeisis that accompanies transfusion may also contribute to the increased anemia observed follo wing a DHTR. Marked ret iculocytopenia is not always a feature of DHTR. As patients with SCD have a shortened RBC survival, suppression of erythropoiesis has a profound effect on hemoglobin concentration compared to patients with normal red cell lifespan.
3-The theory of inflammation SCD has been postulated to be a chronic inflammatory disease. One possibility is that a non-clinically significant antibody may become significant when the donor RBCs undergo accelerated senescence in the bloodstream. This mechanis m wh ich worsens anaemia fo llo wing RBC transfusion still re mains controversial. Based on the finding of erythroid hyperplasia on a bone marrow aspirate during DHTR, a more recent case report suggests that the observed reticulocytopenia is not due to suppression of erythropoiesis, but rather is likely related to peripheral RBC consumption. While no experimental data were provided, a few authors postulated that this could be related to enhanced macrophages activation [25, 26, 27] .
4-The murine models of DHTR The murine models of DHTR have strongly demonstrated that SCD is characterized by chronic inflammat ion. It is possible that inflammation may play a role in the high rate of alloimmunization observed in these patients. However, there are, to date, no published data in SCD patients [28] .
5-The DHTR and HLA types. Associations of HLA types with alloimmunization in SCD patients with nu merous transfusions have been described [29, 30] . More recently, a case-controlled study demonstrated associations of allo immun ization with particular HLA subtypes [31] . The HLA -DRB1*1503 allele was associated with an increased risk of allo immun izat ion [26, 28, 32] , while the HLA-DRB1*0901 allele appeared to confer protection from developing alloantibodies.
Specific risk factors for DHTR in patients without detectable antibodies are unknown. Consequently, patients at risk fo r a first or recurrent episode of DHTR cannot be identified.
Clinical Features
The clinical features of DHTR include [1, 20, 23, 25, [33] [34] [35] :
Fever and sickle pain : sy mptoms that could have been easily mistaken for a simp le VOC in the SCD population.
Develop ment of severe anemia after t ransfusion: posttransfusion hemoglobin (Hb) level lower than the pretransfusion value.
Evidence of hemolysis (hemoglobinuria, hyperbilirubinemia and raised lactate dehydrogenase (LDH).
A fall in absolute reticulocyte count (decrease from patient's usual base level).
Recovery manifested by a rise in Hb and reticulocyte count.
Additional transfusion may exacerbate ongoing hemolysis (may lead to protracted course or even death).
Further classified into -acute(in the acute form of DHTR, both autologous cells and transfused cells are destroyed in the absence of red cell alloantibodies).
-and delayed form (in the delayed form of DHTR, new RBC alloantibodies are often identified in post-transfusion patients' samples).
DHTR may recur following subsequent transfusion (although this is extremely rare).
Diagnosis
The diagnosis of a DHTR is often difficult and delayed. Clin icians in charge of SCD patients should sufficiently be sensitized and informed on this co mplication. The initial sympto ms of DHTR are often co mp lex and mimic other complications of SCD such as severe VOC. Hemolysis is often present in these patients. Reticu locytopenia may mimic ap lastic crisis. DHTR may be more co mmon than is generally recognized and should be considered when a patient has a sickle cell pain crisis approximately 5-15 days after receiving a transfusion. Because of difficu lties in getting compatible blood for future transfusions, it is important to identify the responsible red cell antigen at the time of the DHTR.
It is important that DHTR be included in the differential diagnosis of severe acute pain episodes and decreasing Hb (often lower than it was at the time of o rig inal t ransfusion), following a RBC t ransfusion in a patient with SCD.
Laboratory testing should include a co mp lete blood count with reticulocyte count, an antibody screening (indirect antiglobulin test and direct antiglobulin test) to detect new RBC alloantibodies and/or autoantibodies and a Hemoglobin electrophoresis. Blood chemistry testing should include a serum bilirubin (total and indirect) and LDH to estimate for increased hemolysis, and a urine sample to measure hemoglobinuria [18] .
Inability to identify a new antibody does not exclude the diagnosis of a DHTR, and in many cases, the antibody screening rema ins negative. A hemoglobin electrophoresis is also helpful in establishing the diagnosis of a DHTR. Hemoglobin electrophoresis often demonstrates total or near total destruction of donor erythrocytes, indicated by a lack of hemoglobin A in the specimen [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . The increase in HbS percentages indicating destruction of the transfused RBCs confirms the diagnosis of DHTR [25, 34, 36, 37, 38] .
Treatement
Although DHTR is a serious and potentially lifethreatening complication in ch ildren with SCD, a standard evidence-based approach to therapy has not yet been established. Standard treatment of DHTR includes hospitalization, hydration, administration of intravenous immunoglobulins, corticosteroids or both and recently Ritu ximab [3, 5, 9, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . Ho wever, no randomized controlled trials have been carried out to assess treatments for SCD patients with DHTR. Continuation of blood transfusion may be lethal, as this can further exacerbate hemolysis. Fo r those who develop severe acute hemolysis, Corticosteroids (CS ) are believed to be acceptable therapeutic options, because of their potent immunosuppressive properties [12, 51] . In SCD patients however, there is controversy concerning the effects of steroids. The high frequency of rebound attacks and readmission in SCD children treated with dexamethasone for painful crises or moderate acute chest syndromes argues against the use of CS in these patients [51, 52] .
In addition, severe pain episodes and stroke were reported to occur in four SCD patients after ad ministration of steroids for rheumatoid arthritis and autoimmune hepatitis [55, 56, 57] . More recently, long-term administration of steroids for the treatment of auto-immune diseases in SCD children was reported to be poorly tolerated with worsening of the course of SCD [56] . The basis for the association between CS and the neurological complications in children is speculative [3] . CS o ften increase blood pressure. However, in severe hemolysis, when corticosteroids become necessary, transfusion therapy designed to maintain the hemoglobin S percentage below 30%, should be considered. Such a protective effect has been recently reported for SCD patients treated with both corticosteroids and transfusion therapy for severe acute chest syndrome [56] . A recent study suggested that hydroxyurea, because of its myelosuppressive effects, could be added to the therapeutic strategy for reducing granulocytosis [3, 58] . Few authors have also used high doses of erythropoietin, although baseline levels are like ly to be elevated in patients with normal renal function. Pain episodes and other complications associated with DHTR should be treated as required. Immune-modulating medicat ions provide an exciting possibility for new modalit ies of DHTR prevention. Although clinical trials are lacking, a case report presented a patient with three prior ep isodes of DHTR for who m ritu ximab, a monoclonal antibody that targets B cells by binding with CD20, allowed successful transfusion [49] . Th is will likely be an active area of research in upcoming years.
Finally, patients should be educated about DHTR, providing them with a letter (or card) that exp lains this complication and listing any known alloantibodies, so that med ical providers who are otherwise not familiar with the patient's medical history avoid unnecessary transfusions.
Conclusion
Since DHTR frequently mimics other manifestations of SCD and since post-transfusion screening tests are usually negative, its diagnosis may be underestimated in SCD patients. Patients in whom the diagnosis of DHTR is missed may receive repeated transfusions, which may contribute to the mortality associated with SCD. The high proportion of DHTR cases without identifiable antibodies suggests that different factors are involved in the physiopathology of this potentially life-threatening complication. A mong these factors, inflammation may play a substantial role. Further research on genetic associations with DHTR will likely provide considerable help in elucidating risk factors, and perhaps the pathogenesis, of this syndrome. M inimizing RBC transfusion and the use of more extensive phenotypic matching of b lood, particularly the Rh and Kell blood group systems, when transfusion is required are essential to decrease the risk for allo immunizat ion.
The optimal t reatment of DHTR is still not defined. However, many patients appear to respond to treatment with high-dose steroids, with or without intravenous immunoglobulin. More studies are needed to define the optimal treat ment of this life threatening complication in SCD.
